Obesity in type 2 diabetes: Recommendations from guidelines are largely consistent

July 30, 2012, Institute for Quality and Efficiency in Health Care

On 10th July 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based guidelines for the treatment of obesity in type 2 diabetes. The aim of the report was to identify those recommendations from current guidelines of high methodological quality that may be relevant for a possible new obesity module in the disease management programme (DMP) for type 2 diabetes.

Diet, exercise and behavioural therapy generally advised

IQWiG found that the recommendations of the various guidelines for the treatment of people with who are also grossly overweight were more or less consistent: in general, alongside weight reduction, diet, exercise and behavioural therapy were also advised. Above a certain (BMI), some guidelines also mention drugs to aid weight reduction (BMI ≥ 27 kg/m²) or surgery - for example a gastric bypass (BMI ≥ 35 kg/m²) - as a treatment option. However, the strength of the recommendation, i.e. whether the particular intervention "could", "should" or "must" be used, varies between the individual guidelines. The level of evidence, i.e. the extent to which the recommendations are backed up by results from studies, also differs.

Systematic reviews do not report patient-relevant outcomes

In accordance with the commission received from the Federal Joint Committee (G-BA), the Institute searched for and evaluated systematic reviews, as well as guidelines. The aim was to compare the recommendations of the guidelines with the conclusions of the reviews, i.e. the scientific evidence from studies. However, IQWiG was unable to identify any reviews that were based on the results of studies of high and summarized the relevant results for the treatment of people who suffered from both type 2 and obesity.

Furthermore, the systematic reviews reported largely metabolic parameters, but no patient-relevant outcomes such as blindness or amputation. This means that the conclusions in the guidelines are, for the most part, not supported by evidence from systematic reviews.

Procedure of report production

IQWiG published the preliminary results in the form of the preliminary report in October 2011 and interested parties were invited to submit comments. When the commenting procedure ended, the preliminary report was revised and sent as a final report to the contracting agency, the Federal Joint Committee, in May 2012. The written comments are published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.

On 10th July 2012, the German Institute for Quality and Efficiency in (IQWiG) published the results of a literature search for evidence-based guidelines for the treatment of obesity in type 2 diabetes. The aim of the report was to identify those recommendations from current guidelines of high methodological quality that may be relevant for a possible new obesity module in the disease management programme (DMP) for type 2 diabetes.

Diet, exercise and behavioural therapy generally advised

IQWiG found that the recommendations of the various guidelines for the treatment of people with type 2 diabetes who are also grossly overweight were more or less consistent: in general, alongside weight reduction, diet, exercise and behavioural therapy were also advised. Above a certain Body Mass Index (BMI), some guidelines also mention drugs to aid (BMI ≥ 27 kg/m²) or surgery - for example a gastric bypass (BMI ≥ 35 kg/m²) - as a treatment option. However, the strength of the recommendation, i.e. whether the particular intervention "could", "should" or "must" be used, varies between the individual guidelines. The level of evidence, i.e. the extent to which the recommendations are backed up by results from studies, also differs.

Systematic reviews do not report patient-relevant outcomes

In accordance with the commission received from the Federal Joint Committee (G-BA), the Institute searched for and evaluated systematic reviews, as well as guidelines. The aim was to compare the recommendations of the guidelines with the conclusions of the reviews, i.e. the scientific evidence from studies. However, IQWiG was unable to identify any reviews that were based on the results of studies of high methodological quality and summarized the relevant results for the treatment of people who suffered from both type 2 diabetes and obesity.

Furthermore, the systematic reviews reported largely metabolic parameters, but no patient-relevant outcomes such as blindness or amputation. This means that the conclusions in the are, for the most part, not supported by evidence from systematic reviews.

Procedure of report production

IQWiG published the preliminary results in the form of the preliminary report in October 2011 and interested parties were invited to submit comments. When the commenting procedure ended, the preliminary report was revised and sent as a final report to the contracting agency, the Federal Joint Committee, in May 2012. The written comments are published in a separate document at the same time as the final report. The was produced in collaboration with external experts.

Explore further: DMP for diabetes type 2: Current guidelines indicate some need for revision

More information: The following executive summary ( www.iqwig.de/download/V09-02_E … _type_2_diabetes.pdf ) provides an overview of the background, methods and further results of the final report.

Related Stories

DMP for diabetes type 2: Current guidelines indicate some need for revision

January 3, 2012
On 3 January 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with diabetes ...

Guidelines on rare diseases: Methods on handling evidence neither identified nor required

April 28, 2011
People with rare diseases have the same right to high-quality health care in line with current medical knowledge as other patients do. However, relevant and reliable clinical studies on rare diseases are often lacking. Among ...

Elevated cholesterol levels: Benefit of ezetimibe is not proven

September 14, 2011
Elevated blood cholesterol levels are regarded as a risk factor for heart attacks and other cardiovascular diseases. However, this does not necessarily mean that every cholesterol-lowering drug can also prevent heart attacks. ...

Benefit of blood glucose lowering to near-normal levels remains unclear

July 14, 2011
Whether patients with type 2 diabetes mellitus benefit from attempts to lower their blood glucose levels to near-normal levels through treatment ("intensive blood glucose control") remains an unanswered question. The studies ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Thirty-year study shows women who breastfeed for six months or more reduce their diabetes risk

January 16, 2018
In a long-term national study, breastfeeding for six months or longer cuts the risk of developing type 2 diabetes nearly in half for women throughout their childbearing years, according to new Kaiser Permanente research published ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.